Edgewise Therapeutics Q1 2023 Earnings Report
Key Takeaways
Edgewise Therapeutics started 2023 by advancing its LYNX and CANYON clinical trials of EDG-5506 and completing IND-enabling studies of EDG-7500. They plan to share 12-month ARCH open label data and interim Duchenne data from the Phase 2 LYNX trial and initiate a potentially registration-enabling cohort in CANYON and a Phase 1 trial for EDG-7500.
Advanced Phase 2 trials of EDG-5506 in Becker muscular dystrophy (BMD, CANYON) and Duchenne muscular dystrophy (DMD, LYNX).
Advanced exercise challenge study of EDG-5506 in Limb girdle muscular dystrophy 2I, BMD and McArdle Disease (LGMD2I/R9, BMD, McArdle, DUNE).
Advanced IND-enabling studies of EDG-7500, a novel sarcomere modulator for hypertrophic cardiomyopathy (HCM); Phase 1 start expected in 2H2023.
Cash, cash equivalents and marketable securities of $328 million as of March 31, 2023.
Edgewise Therapeutics
Edgewise Therapeutics
Forward Guidance
Edgewise Therapeutics anticipates sharing 12-month ARCH open label data and interim Duchenne data from its Phase 2 LYNX trial during the remainder of 2023. They plan to initiate a potentially registration-enabling cohort in CANYON and a Phase 1 trial for EDG-7500 in healthy volunteers.
Positive Outlook
- Sharing 12-month ARCH open label data.
- Sharing interim Duchenne data from Phase 2 LYNX trial.
- Initiating a potentially registration-enabling cohort in CANYON.
- Initiating a Phase 1 trial for EDG-7500 in healthy volunteers.